Eagle Health Investments LP Blueprint Medicines Corp Transaction History

Eagle Health Investments LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$54.1 - $110.08 $1.19 Million - $2.43 Million	-22,088 Reduced 11.47%	170,551 $10.9 Million
Q4 2021 Feb 10, 2022	BUY	$94.25 - $115.99 $1.55 Million - $1.91 Million	16,464 Added 9.35%	192,639 $20.6 Million
Q3 2021 Oct 20, 2021	BUY	$80.98 - $109.47 $2.87 Million - $3.88 Million	35,412 Added 25.16%	176,175 $18.1 Million
Q2 2021 Jul 19, 2021	BUY	$82.78 - $101.0 $629,128 - $767,600	7,600 Added 5.71%	140,763 $12.4 Million
Q1 2021 Apr 23, 2021	BUY	$90.71 - $108.28 $6.45 Million - $7.7 Million	71,103 Added 114.57%	133,163 $12.9 Million
Q4 2020 Feb 04, 2021	BUY	$92.08 - $124.48 $5.71 Million - $7.73 Million	62,060 New	62,060 $6.96 Million

391

68.5M

1.54M

1.08M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.66B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Eagle Health Investments LP, based on Form 13F filings with the SEC.

Stay updated on Eagle Health Investments LP with notifications on news.